{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Z"],"funding":["Xiamen Branch, Zhongshan Hospital, Fudan University of China to Yanfang Wu","Xiamen Medical and Health Key Project to Boheng Zhang","Bethune Charitable Foundation to Zhenzhen Zhang"],"pagination":["3710"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9367476"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(15)"],"pubmed_abstract":["Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) is the mainstay treatment for unresectable hepatocellular carcinoma (uHCC). However, studies investigating different combinations of agents have shown inconsistent results. Here, we used network meta-analysis (NMA) to compare different agents across 41 studies (36 cohort studies and five RCTs) in 11,540 patients. Multiple RCTs and cohort studies were searched to evaluate TACE combined with different TKIs. Outcomes of interest included overall survival (OS), progression-free survival (PFS), and tumor response. NMA used a random-effects consistency model to pool evidence from direct and indirect comparisons. Hazard ratio (HR) and relative risks (RR) with 95% confidence intervals (CI) were analyzed. Further"],"journal":["Cancers"],"pubmed_title":["Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis."],"pmcid":["PMC9367476"],"funding_grant_id":["2020ZSXMYS02","3502Z20191105","BCF-MSD-HCC-20201127-001"],"pubmed_authors":["Zhang Z","Xie X","Guo X","Chen G","Zheng S","Chen X","Chen H","Zhang B","Wu Y","Zheng T"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.","description":"Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) is the mainstay treatment for unresectable hepatocellular carcinoma (uHCC). However, studies investigating different combinations of agents have shown inconsistent results. Here, we used network meta-analysis (NMA) to compare different agents across 41 studies (36 cohort studies and five RCTs) in 11,540 patients. Multiple RCTs and cohort studies were searched to evaluate TACE combined with different TKIs. Outcomes of interest included overall survival (OS), progression-free survival (PFS), and tumor response. NMA used a random-effects consistency model to pool evidence from direct and indirect comparisons. Hazard ratio (HR) and relative risks (RR) with 95% confidence intervals (CI) were analyzed. Further","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-04T10:44:58.734Z","creation":"2025-02-19T03:32:30.535Z"},"accession":"S-EPMC9367476","cross_references":{"pubmed":["35954373"],"doi":["10.3390/cancers14153710"]}}